Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2010 by Hallym University Medical Center.
Recruitment status was Not yet recruiting

Sponsor:

Information provided by (Responsible Party):

Hallym University Medical Center

ClinicalTrials.gov Identifier:

NCT01211886

First received: September 29, 2010

Last updated: October 4, 2011

Last verified: September 2010

History of Changes

Tracking Information
First Received Date ^ICMJE	September 29, 2010
Last Updated Date	October 4, 2011
Start Date ^ICMJE	September 2010
Estimated Primary Completion Date	August 2012 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT01211886 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
Official Title ^ICMJE	Utility of BNP in Patients With Type IV Cardio-renal Syndrome Admitted to the ICU: a Prospective Observational Study
Brief Summary	Admission BNP was a useful marker for diagnosing and predicting type IV cardio-renal syndrome type IV in patients with chronic kidney disease admitted to the ICU for acute heart failure in a retrospective study. Therefore, we aim to prospectively investigate the utility of serum BNP in evaluating the treatment adequacy and predicting future cardiac events in patients with type IV CRS.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Retention: Samples Without DNA Description: Serum sample for BNP level
Sampling Method	Non-Probability Sample
Study Population	Patients with chronic kidney disease admitted to the ICU for acute heart failure (i.e., type IV cardio-renal syndrome)
Condition ^ICMJE	Chronic Kidney Disease Acute Heart Failure
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Not yet recruiting
Estimated Enrollment ^ICMJE	83
Completion Date	Not Provided
Estimated Primary Completion Date	August 2012 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Adult patients aged > 18 years, Patients with chronic kidney disease (Serum Cr > 2.0, Documented medical history of chronic kidney disease Exclusion Criteria: Cardiopulmonary resuscitation, Do-not-resuscitate state, Acute kidney injury, ICU stay < 1 day
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01211886
Other Study ID Numbers ^ICMJE	f2000tj1
Has Data Monitoring Committee	Yes
Responsible Party	Hallym University Medical Center
Study Sponsor ^ICMJE	Hallym University Medical Center
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Hallym University Medical Center
Verification Date	September 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top